The competition to develop a treatment for nonalcoholic steatohepatitis, a serious liver disorder, has another player. 89Bio launched Thursday with $65 million in financing and a lead compound originally developed by Teva Pharmaceutical. San Francisco-based 89Bio says that it has acquired a pipeline of biologic and small molecule drug candidates from Teva (NYSE: TEVA). The […]